SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neopath (NPTH)
NPTH 0.0006000.0%Mar 7 3:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DPRLA who wrote (51)9/26/1997 1:34:00 AM
From: Sigmund   of 178
 
I understand that the company expects to go before the advisory panel in November but that date is not certain. The 25% sort rate (reject 25% of the slides by the machine and have 75% of the slides reviewed by cytotechs) that they are requesting is very low. This makes it easier for them to get approval but reduces the cost savings value to the labs. I understand that if they get this approval they will then apply for a higher sort rate. I was also told that the sort rate that they have been approved for in Japan is 40 or 50% I forget which and that they have been approved for sort rates of 40 or 50% in other geographies. This is all from my broker so I am unable to verify it. Anyone else heard the same thing or different?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News